Loading
A larger South Korean follow-on study developing and validating an artificial intelligence blood test for many cancers.
Yonsei whole-genome cell-free DNA multi-cancer platform: development, validation and confirmation (NCT07598747) is an observational study sponsored by Chang Gon Kim. It builds a database of circulating DNA from people with and without cancer and develops and validates an artificial intelligence platform to detect cancers early.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 6,000 participants, a start on 14 October 2024 and primary completion expected on 13 October 2029.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/